NasdaqCM:EVOK

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. More Details


Snowflake Analysis

Moderate growth potential with imperfect balance sheet.

Share Price & News

How has Evoke Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EVOK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: EVOK's weekly volatility (9%) has been stable over the past year.


Market Performance


7 Day Return

-2.6%

EVOK

0.1%

US Pharmaceuticals

2.8%

US Market


1 Year Return

83.1%

EVOK

5.7%

US Pharmaceuticals

20.7%

US Market

Return vs Industry: EVOK exceeded the US Pharmaceuticals industry which returned 5.7% over the past year.

Return vs Market: EVOK exceeded the US Market which returned 20.7% over the past year.


Shareholder returns

EVOKIndustryMarket
7 Day-2.6%0.1%2.8%
30 Day-25.5%6.4%12.3%
90 Day-30.9%-1.9%6.4%
1 Year83.1%83.1%8.5%5.7%23.4%20.7%
3 Year13.9%13.9%23.9%14.8%47.2%37.4%
5 Year-13.6%-13.6%36.3%20.6%94.1%72.7%

Long-Term Price Volatility Vs. Market

How volatile is Evoke Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Evoke Pharma undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Evoke Pharma is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Evoke Pharma has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Evoke Pharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

97.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EVOK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: EVOK is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: EVOK's is expected to become profitable in the next 3 years.

Revenue vs Market: Insufficient data to determine if EVOK's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if EVOK's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if EVOK's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Evoke Pharma performed over the past 5 years?

8.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EVOK is currently unprofitable.

Growing Profit Margin: EVOK is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: EVOK is unprofitable, but has reduced losses over the past 5 years at a rate of 8.5% per year.

Accelerating Growth: Unable to compare EVOK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EVOK is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.8%).


Return on Equity

High ROE: EVOK's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Evoke Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: EVOK has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: EVOK has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: EVOK has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: EVOK's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EVOK has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: EVOK has sufficient cash runway for 1 years if free cash flow continues to grow at historical rates of 12.9% each year.


Next Steps

Dividend

What is Evoke Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate EVOK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EVOK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EVOK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EVOK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EVOK's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

13.4yrs

Average board tenure


CEO

Dave Gonyer (56 yo)

13.67yrs

Tenure

US$1,181,587

Compensation

Mr. David A. Gonyer, also known as Dave, R.Ph., is a Co-Founder of Evoke Pharma, Inc. and has been its Chief Executive Officer and President since March 2007. Mr. Gonyer held senior management positions bo...


CEO Compensation Analysis

Compensation vs Market: Dave's total compensation ($USD1.18M) is above average for companies of similar size in the US market ($USD561.31K).

Compensation vs Earnings: Dave's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
David Gonyer
Co-Founder13.67yrsUS$1.18m1.29%
$ 1.0m
Ann Rhoads
Independent Director7.42yrsUS$73.27k0%
$ 0
Kenneth Widder
Independent Director13.42yrsUS$64.85k0%
$ 0
Todd Brady
Independent Director13.42yrsUS$65.52k0.015%
$ 12.1k
Cam Garner
Independent Chairman of the Board13.42yrsUS$86.34k1.27%
$ 1.0m
Malcolm Hill
Independent Director13.42yrsUS$61.41k0.073%
$ 58.1k

13.4yrs

Average Tenure

59.5yo

Average Age

Experienced Board: EVOK's board of directors are seasoned and experienced ( 13.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.9%.


Top Shareholders

Company Information

Evoke Pharma, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Evoke Pharma, Inc.
  • Ticker: EVOK
  • Exchange: NasdaqCM
  • Founded: 2007
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$79.699m
  • Shares outstanding: 26.39m
  • Website: https://www.evokepharma.com

Number of Employees


Location

  • Evoke Pharma, Inc.
  • 420 Stevens Avenue
  • Suite 370
  • Solana Beach
  • California
  • 92075
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EVOKNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDSep 2013
EV0DB (Deutsche Boerse AG)YesCommon StockDEEURSep 2013

Biography

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopram...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/28 00:45
End of Day Share Price2020/11/27 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.